---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-062544"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2024-05-16T23:59:59+00:00"
generated_at: "2026-06-01T19:13:46.776610+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma Q1 2024 net loss $5.0M; cash $16.4M, extended by $14M April raise

## Summary
- Cash $16.4M at March 31, 2024; raised $14M in April from TPAV/OrbiMed, funding into Q4 2024.
- Net loss $5.0M ($0.24/shr) vs $5.8M ($0.28/shr) in Q1 2023; R&D down to $1.9M from $4.1M.
- Completed acquisition of Trawsfynydd and concurrent $14M private placement in April 2024.
- Initiated Phase 1 dosing for COVID candidate ratutrelvir; last dose cohort for narazaciclib done.
- Plans Phase 2 for influenza and COVID in H2 2024; topline data expected H1 2025.

## SEC filing metadata
- accession: 0001104659-24-062544
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2024-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465924062544/0001104659-24-062544-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465924062544/tm2414653d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-062544
- JSON: https://secwatch.observer/filing/0001104659-24-062544.json
- Plain text: https://secwatch.observer/filing/0001104659-24-062544.txt

## Key facts
- Earnings Releases
  Traws Pharma, Inc. reported the first quarter of 2024 results: revenue fifty-six thousand dollars, net income $5.0 million, or $0.24 per share, EPS $0.24 per share.
  - Period: the first quarter of 2024
  - Revenue: fifty-six thousand dollars
  - Net income: $5.0 million, or $0.24 per share
  - EPS: $0.24 per share
  - Result: reported results
  source text: Revenue was fifty-six thousand dollars for the first quarter of 2024, consistent with the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130598/000110465924062544/0001104659-24-062544-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.